FDA weighs black box warning for two eczema creams

Share this article:
The FDA convened an outside panel of experts this week to consider adding black box labeling to two prescription eczema creams to warn they might increase the risk of certain cancers, especially in children. The panel discussed Novartis' Elidel and Fujisawa Pharmaceuticals' Protopic after 13 reports of skin cancer and lymphoma in children and adults. Novartis said there was no evidence
Elidel causes lymphoma, noting the number of lymphomas in question "is below the number typically observed in the general population." Fujisawa said it did not believe Protopic raised the risk of skin cancer or lymphoma and that the cream "has a favorable benefit-risk ratio."
Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.